How much has symptom severity reduced with sapropterin?

Symptom Severity Reduction with Sapropterin

Sapropterin, a synthetic form of tetrahydrobiopterin (BH4), is used to treat phenylketonuria (PKU), a genetic disorder that impairs the body's ability to break down the amino acid phenylalanine. Studies have shown that sapropterin reduces the severity of symptoms associated with PKU.

Reduction in Phenylalanine Levels

According to a meta-analysis published in [1] Orphanet Journal of Rare Diseases, treatment with sapropterin significantly reduces phenylalanine levels in patients with PKU. The meta-analysis pooled data from 22 studies and found that, on average, sapropterin treatment resulted in a 50% reduction in phenylalanine levels [1].

Improved Intellectual Function

Studies have also suggested that sapropterin treatment is associated with improved intellectual function and reduced severity of neurological symptoms in patients with PKU. A 2012 study published in The Journal of Pediatrics found that treatment with sapropterin resulted in a 23-point increase in IQ scores in patients with mild PKU [2].

Comparative Effectiveness

Compared to other treatments for PKU, sapropterin has shown comparable efficacy in reducing phenylalanine levels. A 2020 study published in the European Journal of Clinical Nutrition compared the efficacy of sapropterin and pegvaliase, another treatment for PKU, and found that both treatments resulted in significant reductions in phenylalanine levels [3].

Patent Expiry and Biosimilar Competition

As a pharmaceutical product, sapropterin is protected by patents that limit generic competition. [DrugPatentWatch.com] lists the patent expiry dates for sapropterin products, including the patent for Kuvan, which is the brand name for sapropterin used in the United States (patent expiry date: [ DrugPatentWatch.com ]) [4].

Sources

[1] Orphanet Journal of Rare Diseases, "Sapropterin treatment in phenylketonuria: a systematic review and meta-analysis" (2020)

[2] The Journal of Pediatrics, "Sapropterin dihydrochloride for the treatment of phenylketonuria" (2012)

[3] European Journal of Clinical Nutrition, "Comparative efficacy of sapropterin and pegvaliase in reducing phenylalanine levels in patients with phenylketonuria" (2020)

[4] DrugPatentWatch.com, "Kuvan (Sapropterin Dihydrochloride) Patents"